Codexis (NASDAQ: CDXS) — Perfil da empresa, notícias e dados financeiros
Codexis develops engineered enzymes for pharmaceuticals and bioindustrial applications, focusing on sustainability and efficiency.
Codexis
Codexis (NASDAQ:CDXS) specializes in developing engineered enzymes for pharmaceutical, bioindustrial, and diagnostic applications. The company's innovative approach to enzyme engineering enables the creation of highly optimized biocatalysts that drive efficiency and cost-effectiveness in drug manufacture, the production of bio-based chemicals, and diagnostic tests. Codexis is focused on leveraging its proprietary CodeEvolver® technology platform to accelerate the development of novel enzymes and to form strategic partnerships and collaborations across various industries. With a strong commitment to sustainability, Codexis aims to contribute to a greener and more sustainable future through its enzyme engineering advancements, targeting objectives that include expanding its enzyme product portfolio and entering new markets.
Resumo
Operações
Produtos e/ou serviços de Codexis
- Biotherapeutics: Enzyme engineering for developing novel enzymes for therapeutic applications, incorporating protein engineering for targeted drug delivery and disease treatment.
- Codex Biocatalyst Panels: Pre-engineered enzyme kits designed for pharmaceutical and chemical manufacturing, aimed at improving process efficiency and sustainability.
- CodeEvolver: A proprietary platform technology for enzyme optimization, enabling the rapid development of customized solutions for biotherapeutics, fine chemicals, and agrochemicals.
- Custom Enzyme Development Services: Tailored enzyme engineering and development services for unique industrial and pharmaceutical applications, leveraging advanced protein engineering techniques.
- Food and Nutrition Ingredients: Development of enzymes for the production of health-promoting ingredients and processing aids for the food and beverage industry.
- Life Science Tools and Services: Offering enzymes and enzyme-based kits for genomics, drug discovery, and biotherapeutic research, assisting scientific investigation and innovation.
equipe executiva do Codexis
- Alison MoorePresident, CEO & Director
- Georgia L. ErbezCFO & Chief Business Officer
- Stefan LutzChief Scientific Officer
- Britton JimenezSenior Vice President of Sales & Marketing
- Karen Frechou-ArmijoSenior VP & Head of Human Resources
- John SchiffhauerSenior Vice President of Intellectual Property
Últimas notícias sobre a Codexis
Principais indicadores financeiros
Resultados divulgados pela Codexis, em USD.
- Cap. de mercado
- 138 mi
- Receita (TTM)
- 77,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- -39.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 70,4 mi | -38,3 mi | -44 mi | |
| 59,3 mi | -58,5 mi | -65,3 mi | |
| 70,1 mi | -68,1 mi | -76,2 mi | |
| 138,6 mi | -34,9 mi | -33,6 mi |